Replies to post #218471 on Biotech Values

[DewDiligence]

TOCA -33%/AH on continuation to final analysis of phase-3 in glioma:

https://finance.yahoo.com/news/tocagens-toca-5-pivotal-phase-200500398.html

Many investors were banking on success at the interim analysis, evidently.